194 related articles for article (PubMed ID: 7997072)
1. Muscarinic receptors and novel strategies for the treatment of age-related brain disorders.
Ehlert FJ; Roeske WR; Yamamura HI
Life Sci; 1994; 55(25-26):2135-45. PubMed ID: 7997072
[TBL] [Abstract][Full Text] [Related]
2. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
Lazareno S; Popham A; Birdsall NJ
J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
[TBL] [Abstract][Full Text] [Related]
3. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.
Clader JW; Wang Y
Curr Pharm Des; 2005; 11(26):3353-61. PubMed ID: 16250841
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
Verma S; Kumar A; Tripathi T; Kumar A
J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
[TBL] [Abstract][Full Text] [Related]
5. Muscarinic M(1) agonists in the treatment of Alzheimer's disease.
Korczyn AD
Expert Opin Investig Drugs; 2000 Oct; 9(10):2259-67. PubMed ID: 11060805
[TBL] [Abstract][Full Text] [Related]
6. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
7. Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors.
Lazareno S; Popham A; Birdsall NJ
J Mol Neurosci; 2003; 20(3):363-7. PubMed ID: 14501021
[TBL] [Abstract][Full Text] [Related]
8. Bitopic Binding Mode of an M
Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
[TBL] [Abstract][Full Text] [Related]
9. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease.
Koch HJ; Haas S; Jürgens T
Curr Med Chem; 2005; 12(24):2915-21. PubMed ID: 16305479
[TBL] [Abstract][Full Text] [Related]
10. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies.
Flynn DD; Ferrari-DiLeo G; Levey AI; Mash DC
Life Sci; 1995; 56(11-12):869-76. PubMed ID: 10188787
[TBL] [Abstract][Full Text] [Related]
11. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Messer WS
J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic opportunities for muscarinic receptors in the central nervous system.
Felder CC; Bymaster FP; Ward J; DeLapp N
J Med Chem; 2000 Nov; 43(23):4333-53. PubMed ID: 11087557
[No Abstract] [Full Text] [Related]
14. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
[TBL] [Abstract][Full Text] [Related]
15. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; El-Fakahany EE; Tucek S
Mol Pharmacol; 1997 Jul; 52(1):172-9. PubMed ID: 9224827
[TBL] [Abstract][Full Text] [Related]
16. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Fisher A
Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
[TBL] [Abstract][Full Text] [Related]
18. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes.
Birdsall NJ; Farries T; Gharagozloo P; Kobayashi S; Kuonen D; Lazareno S; Popham A; Sugimoto M
Life Sci; 1997; 60(13-14):1047-52. PubMed ID: 9121346
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.
Eglen RM
Auton Autacoid Pharmacol; 2006 Jul; 26(3):219-33. PubMed ID: 16879488
[TBL] [Abstract][Full Text] [Related]
20. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
